A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

Summary

The study is being conducted to evaluate the efficacy and safety of HRS9531 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Semaglutide QW for 36 weeks and 52 weeks.

Timeline

Start

2024-10-31

Primary completion

2026-09-30

Completion

2026-09-30

Outcome

Met primary endpoint

release “（HRS9531-303）取得积极顶线结果 1 。瑞普泊肽注射液4 mg和2 mg两个剂量组均达到预设的主要终点” hengrui.com ↗

Drugs

Indications